Bolero-2 Clinical Trial

Industry Update: The Latest Developments In Therapeutic Delivery
Of relapse and delay of progression of physical disability in adults with multiple sclerosis, while the topline BOLERO-2 clinical trial results presented at the 2011 European Multidisciplinary Cancer Congress in Stockholm, Sweden showed ... Access Full Source

AACR Interview With José Baselga, M.D., Ph.D. - YouTube
AACR Interview with José Baselga, M.D., Ph.D. CLEOPATRA Pertuzumab Trial Increases Progression-Free Survival - Duration: 11:11 57:39. Jose Calderón 1,001,999 views. 57:39 AACR 2013: Myc inhibition in pre-clinical mouse models - Duration: 7:53. ecancer 440 ... View Video

Safety And Efficacy Of Everolimus With Exemestane Vs ...
Clinical Practice Points The BOLERO-2 trial showed that the combination of EVE Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2 ... Read Full Source

Estimation Of The Quality Adjusted Progression Free Survival ...
Aims to estimate the QAPFS of the treatment arms of the BOLERO-2 trial. Methods: For each treatment arm of the trial, QAPFS was estimated by multiplying the overall health utility weights associated with PFS (taking into consideration disutlities asso - ... Fetch Here

Anastrozole And Everolimus In Advanced Gynecologic And Breast ...
Anastrozole and everolimus in advanced gynecologic and breast malignancies: activity and molecular alterations in the PI3K/ The Bolero-2 trial (trial registration ID: NCT00863655), correlates of clinical response can be identified. ... Fetch Document

One Step Forward, Two Steps Back: The Story Of Everolimus In ...
Viewpoints and debate One step forward, two steps back: The story of everolimus in advanced breast cancer Saroj Niraula a, *, Alberto Ocana b, Eitan Amir c ... Doc Retrieval

Analysis Of Blood Samples Finds ESR1 Gene Mutations Are ...
Previously published results from the phase III BOLERO-2 clinical trial showed that adding everolimus to the standard hormonal therapy exemestane improved outcomes for postmenopausal women with ER-positive, locally advanced or metastatic breast cancer that has ... Read Content

Reading The Literature On clinical trials With A Critical Eye ...
Bolero-2: time on study (courtesy of Greg Pond) Censoring bias: Patients who withdraw from a study (for toxicity or other reasons) are censored clinical trial - chronic toxicity, associated with targeted agents may occur late. 3. ... View Full Source

Everolimus In HR-Positive Advanced Breast Cancer - Nejm.org
Clinical benefit rate and time to progression are more relevant measures of efficacy than response rate, because progression usually triggers a change results of the BOLERO-2 Phase III trial. Cancer Res 2011;71: Suppl:105s. abstract. 3. ... Access Full Source

Effect Of Visceral Metastases On The Efficacy And Safety Of ...
Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: Subgroup analysis from the BOLERO-2 studyq ... Return Doc

Everolimus For The Treatment Of Advanced Breast Cancer
1 October 10, 2011 Submission Request National Comprehensive Cancer Network RE: Clinical Evidence in Support of Afinitor® (everolimus) in Advanced Breast Cancer ... Visit Document

Landmarks - Oncology Ex
Landmarks Breast cancer TRIAL SUMMARY: BOLERO-2 Phase III trial results Hortobagyi gN, Piccart M, rugo H et al. everolimus for postmenopausal women with advanced breast cancer: updated results of the bOLerO-2 Other clinical studies support BOLERO-2 conclusions, ... Get Doc

Year: 2015 Everolimus In The Treatment Of Metastatic Breast ...
The BOLERO-2 trial demonstrated that the everolimus/ exemestane combination was associated with a longer time to objective of the trial is to estimate the clinical efficacy of everolimus in combination with endocrine therapy as assessed ... Retrieve Content

Resistance Mutations Identified In ER-Positive Metastatic ...
Also analyzed samples from patients who took part in the BOLERO-2 clinical trial that enrolled metastatic breast cancer patients whose cancer had progressed while on aromatase inhibitor therapy. Of 44 metastatic samples, 5 (11%) had an ESR1 mutation. ... View This Document

Denise A Yardley, MD - Research To Practice
13 This trial was performed in a much earlier clinical setting than that DR YARDLEY: which led to the approval of eribulin. So it was designed to move eribulin up earlier in ... Content Retrieval

Www.medscape.com Major Advances In Clinical Cancer Research ...
Major Advances in Clinical Cancer Research in . 2012 . Zosia Chustecka . Dec 19, 2012 . the 724-patient BOLERO-2 trial, which was halted early because of the benefit observed. The combination of everolimus plus exemestane increased the median time to disease ... Content Retrieval

Efficacy And Tolerance Of Everolimus In 123 Consecutive ...
Clinical practice abstract Background: Since the publication of the Bolero-2 trial, everolimus has entered the routine care for advanced endocrine resistant luminal breast cancer (BC). HER2-negative breast cancer patients, two years after the market-ing authorization was issued. ... Document Viewer